Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)

NCT04724109 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT04724109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04724109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)
Lead sponsor
Eisai Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
October 14, 2020
Completion date
October 13, 2022
Enrollment
1,088 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease